Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing

NACompletedINTERVENTIONAL
Enrollment

185

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

July 17, 2019

Study Completion Date

July 17, 2019

Conditions
Gastroesophageal Reflux Disease
Interventions
GENETIC

CYP2C19 genotyping

All proton pump inhibitors are metabolized in part by the CYP2C19 enzyme, which is encoded by the highly polymorphic CYP2C19 gene. Based on variations within this gene the effectiveness of the drug may be reduced.

Trial Locations (2)

32610

University of Florida, Gainesville

32827

Nemours Children's Hospital, Orlando

All Listed Sponsors
collaborator

Nemours Children's Hospital

OTHER

collaborator

National Human Genome Research Institute (NHGRI)

NIH

lead

University of Florida

OTHER

NCT02930824 - Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing | Biotech Hunter | Biotech Hunter